C|M|Law’s James A. Thomas Distinguished Professor of Law Chris Sagers had a new post  on the HuffingtonPost last week concerning last week’s Supreme Court decision in Federal Trade Commission v. Actavis, Inc.  In the case, the Court held that so-called “reverse payment” or “pay for delay” agreements between branded drug manufacturers and would-be generic competitors are not only subject to antitrust law, but are likely illegal in any case in which the reverse payment is “large.”  Sagers offers thoughts about why the case matters not just for the narrow context of the drug sector, but for antitrust law and competition generally.

You may read Sagers’ post here:

http://www.huffingtonpost.com/chris-sagers/the-drug-patents-case-the_b_3480866.html